STOCKS TELEGRAPH

Tag: MIRA

  • MIRA Pharmaceuticals (MIRA) Surges In After-Hours Following Key Developments

    In a sudden twist of events, MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) experienced a staggering 82% surge in its stock price during after-hours trading, almost doubling its value to an impressive $1.73. This significant leap comes on the heels of a rather subdued trading day where the stock showed minimal movement, slipping by a mere 0.1%.

    Promising Momentum Driven by Recent Regulatory Filing

    The sudden spike in MIRA’s stock price appears to be intricately tied to a recent 8k filing, illuminating crucial updates regarding the company’s innovative drug candidate, MIRA1a. This oral pharmaceutical marijuana compound holds the potential in addressing the debilitating effects of anxiety and cognitive decline, particularly prevalent in individuals grappling with early-stage dementia.

    Notably, regulatory authorities have determined that neither MIRA1a nor its counterpart, Ketamir-2, fall under controlled substance classifications.

    Breakthrough Discovery Ignites Optimism

    MIRA Pharmaceuticals recently unveiled a groundbreaking revelation stemming from collaborative discussions with its manufacturing partners. This revelation centers on the identification of a novel molecule, MIRA-55, distinct from the originally intended MIRA1a compound.

    Initial assessments suggest that MIRA-55 boasts heightened potency and efficacy compared to its predecessor, paving the way for a provisional patent application aimed at securing global protection.

    Strategic Alliances and Future Prospects

    The strategic partnership forged last month between MIRA Pharmaceuticals and Pharmaseed Ltd., a renowned clinical research organization specializing in neurological disorders, heralds a new chapter in the pursuit of innovative therapeutics.

    Together, they embark on a journey to evaluate Ketamir-2, a revolutionary ketamine analog, with aspirations of delivering rapid relief to individuals grappling with major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). This synergistic collaboration underscores MIRA’s commitment to pioneering solutions for mental health challenges.

    Conclusion

    The surge in MIRA Pharmaceuticals’ stock price mirrors growing investor confidence buoyed by significant advancements in the company’s pharmaceutical portfolio. With the emergence of the potent MIRA-55 molecule and strategic alliances firmly established, MIRA Pharmaceuticals stands at the forefront of revolutionizing the treatment landscape for neurologic and neuropsychiatric disorders.

    As stakeholders eagerly anticipate further developments, the trajectory of MIRA Pharmaceuticals underscores its unwavering dedication to reshaping the future of healthcare.

  • What Helped MIRA Pharmaceuticals Recover In Extended Session

    What Helped MIRA Pharmaceuticals Recover In Extended Session

    MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) witnessed a notable upswing of 7.04% in its stock value, reaching $3.42 during the extended trading session on Wednesday. This surge contributed to the partial recovery of MIRA Pharmaceuticals stock, mitigating an 18.08% loss in the regular session and concluding at $3.20. The impetus for this positive momentum was an announcement by MIRA Pharmaceuticals heralding a paradigm shift.

    In a groundbreaking revelation, MIRA Pharmaceuticals (MIRA) disclosed pioneering insights into the cognitive enhancement effects of MIRA1a in normal mice. This unveiling occurred during a presentation at the Grand Rounds of the University of Louisville’s Christine Lee Brown Envirome Institute. This significant finding was delivered by Dr. Adam Kaplin, MD, PhD, President and Chief Scientific Officer at MIRA Pharmaceuticals. He is also an Adjunct Faculty member at Johns Hopkins School of Medicine.

    His presentation focused on the unique properties of THC and MIRA1a, an innovative analog of THC, which were the focus of Dr. Kaplin’s research on psychotropic drug development. The research highlighted that while THC displayed a biphasic response, being therapeutic at low doses but toxic at high doses, MIRA1a exhibited remarkable stability, even at elevated doses, without inducing any toxic side effects.

    Moreover, MIRA1a demonstrated a twofold increase in the performance of normal adult mice in learning and memory tests, underscoring its potential to enhance cognitive abilities beyond conventional thresholds. The revelation of MIRA1a’s profound cognitive enhancement, evident even after a single dose, signifies a transformative breakthrough in neuropsychiatric research.

    This landmark discovery solidifies MIRA Pharmaceuticals’ position at the forefront of innovative developments in psychotropic drug research. With an unwavering commitment to seizing industry-defining opportunities, MIRA Pharmaceuticals stands poised to capitalize on a vast market potential. The company concentrates its efforts on addressing anxiety and neuropathic pain within the expansive traditional neurological markets valued at over $90 billion.

    According to Dr. Kaplin, cognitive impairment can be treated in a revolutionary way, especially in the early stages of dementia, according to his findings. MIRA1a has consistent therapeutic effects, even at high doses, making it a promising candidate to treat neuropsychiatric disorders.